Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies

References

• International Agency for Research on Cancer World Health Organization, PRESS RELEASE N° 263. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 2018. Available from: http://gco.iarc.fr/
   Google Scholar
• Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2018;144(12):32055.
   Web of Science ®Google Scholar
• Bracht K, Nicholls AM, Liu Y, et al. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer. 2010;103(3):340–346.
   PubMed Web of Science ®Google Scholar
• Lim HJ, Gill S, Speers C, et al. Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study. JOP. 2009;5(4):153–158.
   PubMedGoogle Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. JCO. 2008;26(14):2311–2319.
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. JCO. 2010;28(31):4706–4713.
   PubMed Web of Science ®Google Scholar
• Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics. 2014;8:13–25.
   PubMedGoogle Scholar
• Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013;13(8):1187–1196.
   PubMed Web of Science ®Google Scholar
• Goel G, Sun W. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice. J Hematol Oncol. 2015;8:92.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–591.
   PubMed Web of Science ®Google Scholar
• Rao D, Parakrama R, Augustine T, et al. Immunotherapeutic advances in gastrointestinal malignancies. Npj Precis Oncol. 2019;3:4.
   PubMed Web of Science ®Google Scholar
• Zhao B, Wang L, Qiu H, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017;8:3980–4000.
   PubMedGoogle Scholar
• Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and Its role in non-endothelial cells: autocrine signalling by VEGF. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6482/
   Google Scholar
• Bendardaf R, Buhmeida A, Hilska M, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28:3865–3870.
   PubMed Web of Science ®Google Scholar
• Hopirtean C, Nagy V. Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. Clujul Med. 2018;91:12–17.
   PubMedGoogle Scholar
• EGFR epidermal growth factor receptor [ Homo sapiens (human) ]Gene ID: 1956, updated on 13-Jan-2020 Available from: https://www.ncbi.nlm.nih.gov/gene/1956?report=full_report&format=text
   Google Scholar
• Chan DLH, Segelov E, Wong RSH, et al. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6:CD007047.
   PubMedGoogle Scholar
• Greally M, Kelly CM, Cercek A. HER2: an emerging target in colorectal cancer. Curr Probl Cancer. 2018;42:560–571.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.
   PubMedGoogle Scholar
• ERBB2 gene symbol report | HUGO Gene Nomenclature Committee. n.d. Available from: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430
   Google Scholar
• Pectasides E, Bass AJ. ERBB2 emerges as a new target for colorectal cancer. Cancer Discov. 2015;5(8):799–801.
   PubMed Web of Science ®Google Scholar
• Owen DR, Wong H-L, Bonakdar M, et al. Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Cold Spring Harb Mol Case Stud. 2018;4(2):a002535.
   PubMed Web of Science ®Google Scholar
• ERBB3 gene symbol report | HUGO Gene Nomenclature Committee. [cited 2020 Jan 13]. Available from: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3431
   Google Scholar
• Jardé T, Kass L, Staples M, et al. ERBB3 positively correlates with intestinal stem cell markers but marks a distinct non proliferative cell population in colorectal cancer. PLoS One. 2015;10(9):e0138336–e0138336.
   PubMed Web of Science ®Google Scholar
• Huang Y, Xiao D, Burton-Freeman BM, et al. Chemical changes of bioactive phytochemicals during thermal processing. Reference Module in Food Science, Elsevier, 2016. ISBN 9780081005965, Available from: 10.1016/B978-0-08-100596-5.03055-9. (http://www.sciencedirect.com/science/article/pii/B9780081005965030559)
   Google Scholar
• Wang H, Khor TO, Shu L, et al. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. ACAMC. 2012;12(10):1281–1305.
   Web of Science ®Google Scholar
• Gutheil WG, Reed G, Ray A, et al. Crocetin: an agent derived from saffron for prevention and therapy for cancer. CPB. 2012;13:173–179.
   Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–1616.
   PubMed Web of Science ®Google Scholar
• Sun J, Chu Y-F, Wu X, et al. Antioxidant and antiproliferative activities of common fruits. J Agric Food Chem. 2002;50(25):7449–7454.
   PubMed Web of Science ®Google Scholar
• Chu Y-F, Sun J, Wu X, et al. Antioxidant and antiproliferative activities of common vegetables. J Agric Food Chem. 2002;50(23):6910–6916.
   PubMed Web of Science ®Google Scholar
• Chahar MK, Sharma N, Dobhal MP, et al. Flavonoids: a versatile source of anticancer drugs. Phcog Rev. 2011;5:1–12.
   Google Scholar
• McConkey BJ, Sobolev V, Edelman M. The performance of current methods in ligand – protein docking. Curr Sci. 2002;83(7):845–856. Available from: www.jstor.org/stable/24107087
   Web of Science ®Google Scholar
• Pudjiastuti P, Puspaningsih NNT, Siswanto I, et al. Inhibitory activity and docking analysis of antimalarial agents from Stemona sp. toward ferredoxin-NADP + reductase from malaria parasites. J Parasitol Res. 2018;2018(2018):1–6.
   Google Scholar
• Morris GM, Huey R, Olson AJ. Using AutoDock for ligand-receptor docking. Curr Protoc Bioinforma. 2008;24(1):8.14.1–8.14.40.
   Google Scholar
• Verdonk ML, Chessari G, Cole JC, et al. Modeling water molecules in protein − ligand docking using GOLD. J Med Chem. 2005;48(20):6504–6515.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–461.
   PubMed Web of Science ®Google Scholar
• Xin M, Li R, Xie M, et al. Small-molecule Bax agonists for cancer therapy. Nat Commun. 2014;5:4935.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–536.
   PubMed Web of Science ®Google Scholar
• Arao T, Matsumoto K, Furuta K, et al. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells. Anticancer Res. 2011;31(9):2787–2796.
   PubMed Web of Science ®Google Scholar
• RCSB PDB: Homepage. [cited 2020 Jan 13]. Available from: https://www.rcsb.org/
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612.
   PubMed Web of Science ®Google Scholar
• The PubChem Project. [cited 2020 Jan 13]. Available from: https://pubchem.ncbi.nlm.nih.gov/
   Google Scholar
• Pharmacology U, Santos Cerqueira G, dos Santos Silva G, et al. Effects of hecogenin and its possible mechanism of action on experimental models of gastric ulcer in mice. Eur J Pharmacol. 2012;683(1–3):260–269.
   PubMed Web of Science ®Google Scholar
• Kandakumar S, Manju V. Pharmacological applications of isorhamnetin: a short review. Int J Trend Sci Res Dev. 2017;1(4):672–678.ISSN: 2456-6470, Available from: https://www.ijtsrd.com/papers/ijtsrd2202.pdf
   Google Scholar
• Gao Y, Liu F, Fang L, et al. Genkwanin inhibits proinflammatory mediators mainly through the regulation of miR-101/MKP-1/MAPK pathway in LPS-activated macrophages. PLoS One. 2014;9(5):e96741.
   PubMed Web of Science ®Google Scholar
• Xu W-C, Shen J-G, Jiang J-Q. Phytochemical and biological studies of the plants from the genus Daphne. Chem Biodivers. 2011;8(7):1215–1233.
   PubMed Web of Science ®Google Scholar
• Ren J, Chung SH. Anti-inflammatory effect of $α$-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-$κ$B and mitogen-activated protein kinase pathways. J Agric Food Chem. 2007;55(13):5073–5080.
   PubMed Web of Science ®Google Scholar
• Li J, Wang H, Li J, et al. Discovery of a potential HER2 inhibitor from natural products for the treatment of HER2-positive breast cancer. Int J Mol Sci. 2016;17(7):1055.
   Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109.
   PubMed Web of Science ®Google Scholar